[Federal Register Volume 62, Number 50 (Friday, March 14, 1997)]
[Notices]
[Pages 12217-12218]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-6409]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 97M-0051]


Eurexpan Labo; Premarket Approval of ContaClair Multi-
Purpose Solution

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing its 
approval of the application submitted by the law firm of Akin, Gump, 
Strauss, Hauer and Field, as the United States Representative on behalf 
of Eurexpan Labo, 41120 Cellettes, France, for premarket approval, 
under the Federal Food, Drug, and Cosmetic Act (the act), of 
ContaClair Multi-Purpose Solution. FDA's Center for Devices 
and Radiological Health (CDRH) notified the applicant, by letter of 
June 20, 1996, of the approval of the application.

DATES: Petitions for administrative review by April 14, 1997.

ADDRESSES: Written requests for copies of the summary of safety and 
effectiveness data and petitions for administrative review to the 
Dockets Management Branch (HFA-305), Food and Drug Administration, 
12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: James F. Saviola, Center for Devices 
and Radiological Health (HFZ-460), Food and Drug Administration, 9200 
Corporate Blvd., Rockville, MD 20850, 301-594-1744.

SUPPLEMENTARY INFORMATION: On December 19, 1991, the law firm of Akin, 
Gump, Strauss, Hauer and Field, as the United States Representative on 
behalf of Eurexpan Labo, 41120 Cellettes, France, submitted to CDRH an 
application for premarket approval of ContaClair Multi-
Purpose Solution. The device is a cleaning, rinsing, disinfecting, and 
storing solution and is indicated for cleaning, rinsing, disinfecting, 
and storing daily and extended wear clear and tinted soft (hydrophilic) 
contact lenses.
    In accordance with the provisions of section 515(c)(2) of the act 
(21 U.S.C. 360e(c)(2)) as amended by the Safe Medical Devices Act of 
1990, this premarket approval application (PMA) was not referred to the 
Ophthalmic Devices Panel of the Medical Devices Advisory Committee, an 
FDA advisory

[[Page 12218]]

committee, for review and recommendation because the information in the 
PMA substantially duplicates information previously reviewed by this 
panel.
    On June 20, 1996, CDRH approved the application by a letter to the 
applicant from the Director of the Office of Device Evaluation, CDRH.
    A summary of the safety and effectiveness data on which CDRH based 
its approval is on file in the Dockets Management Branch (address 
above) and is available from that office upon written request. Requests 
should be identified with the name of the device and the docket number 
found in brackets in the heading of this document.

Opportunity for Administrative Review

    Section 515(d)(3) of the act authorizes any interested person to 
petition, under section 515(g) of the act, for administrative review of 
CDRH's decision to approve this application. A petitioner may request 
either a formal hearing under 21 CFR part 12 of FDA's administrative 
practices and procedures regulations or a review of the application and 
CDRH's action by an independent advisory committee of experts. A 
petition is to be in the form of a petition for reconsideration under 
21 CFR 10.33(b). A petitioner shall identify the form of review 
requested (hearing or independent advisory committee) and shall submit 
with the petition supporting data and information showing that there is 
a genuine and substantial issue of material fact for resolution through 
administrative review. After reviewing the petition, FDA will decide 
whether to grant or deny the petition and will publish a notice of its 
decision in the Federal Register. If FDA grants the petition, the 
notice will state the issue to be reviewed, the form of the review to 
be used, the persons who may participate in the review, the time and 
place where the review will occur, and other details.
    Petitioners may, at any time on or before April 14, 1997, file with 
the Dockets Management Branch (address above) two copies of each 
petition and supporting data and information, identified with the name 
of the device and the docket number found in brackets in the heading of 
this document. Received petitions may be seen in the office above 
between 9 a.m. and 4 p.m., Monday through Friday.
    This notice is issued under the Federal Food, Drug, and Cosmetic 
Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under 
authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) 
and redelegated to the Director, Center for Devices and Radiological 
Health (21 CFR 5.53).

    Dated: January 16, 1997.
Joseph A. Levitt,
Deputy Director for Regulations Policy, Center for Devices and 
Radiological Health.
[FR Doc. 97-6409 Filed 3-13-97; 8:45 am]
BILLING CODE 4160-01-F